UNSPSC 51384524: Flurbiprofen sodium

This classification denotes a cyclooxygenase inhibitor and carbonic anhydrase inhibitor with the molecular formula C15H12FO2.Na.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z5B97MU9K4, chemically known as 4-biphenylacetic acid, 2-fluoro-alpha-methyl- but more generally known as flurbiprofen sodium, which bears US NIH Compound Identifier 3394. European Medicines Agency schedules Flurbiprofen sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02240MIG.

Most nations, for tariff and trade purposes, schedule flurbiprofen sodium under HS 29163900 and SITC 51379. As of Q4 2014, FLURBIPROFEN SODIUM remains US FDA's Preferred Term for this commodity. Flurbiprofen sodium bears US NLM identifiers UMLS ID C0304658 and NCI Concept Code C47997. SMILES: CC(C1CCC(C(C1)F)C2CCCCC2)C(=O)[O-].O.O.[NA+].

UNSPSC 51384524 Flurbiprofen sodium is a Commodity code that in recent state and local procurement activity reflects broader pharmaceutical supply procurement rather than the narrow chemical name alone. State and local health agencies are sourcing pharmaceutical products—including naloxone, generic multi-source drugs, and OTC items—through competitive bidding and cooperative purchasing frameworks. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. Work under the code encompasses manufacturer supply agreements with defined pricing models, product specification compliance (NDC codes, cGMP, DSCSA certification), wholesaler distribution relationships, and quarterly or ongoing fulfillment to public health facilities and programs.

Recent opportunities show activity across Florida, Texas, and Minnesota. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP on January 20, 2026, establishing multiple contracts for generic pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract awards effective July 1, 2026. MMCAP's solicitation emphasizes price competitiveness (75 percent evaluation weight), compliance with FDA and supply-chain security standards, and relationships with authorized wholesalers including AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC.